skip to Main Content

EC Approves Liposomal Irinotecan (Onivyde)for Pancreatic Cancer

EC Approves Liposomal Irinotecan (Onivyde)for Pancreatic Cancer
The European Commission (EC) has approved pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil (5-FU) and leucovorin for patients with metastatic pancreatic adenocarcinoma following progression on a gemcitabine-based therapy.

The approval was based on findings from the phase III NAPOLI-1 trial, which demonstrated a 1.9-month improvement in overall survival (OS) with the addition of liposomal irinotecan to 5-FU and leucovorin. In the combination arm, the median OS was 6.1 months compared with 4.2 months with 5-FU and leucovorin alone (HR, 0.67; 95% CI, 0.49-0.92; P = .012). Read more . . .


Back To Top